IFAN — Palantir Bioceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for Palantir Bioceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2013 August 31st	2014 August 31st	2015 August 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	PROSPECTUS	PROSPECTUS
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-0.019	-0.042	-2.38	0	0
Depreciation
Amortisation
Non-Cash Items	—	—	1.63	—	—
Unusual Items
Other Non-Cash Items
Changes in Working Capital	0.009	-0.051	0.123	0	0
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Cash from Operating Activities	-0.01	-0.092	-0.595	0	0
Capital Expenditures	—	-0.03	-0.072	—	—
Purchase / Acquisition of Intangibles
Software Development Costs
Other Investing Cash Flow Items	—	-0.03	-0.1	0	0
Other Investing Cash Flow
Cash from Investing Activities	—	-0.06	-0.172	0	0
Financing Cash Flow Items	0.006	0.151	0.208	0	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	0.011	0.151	0.905	0	0
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	0.001	-0.001	0.138	0	0